Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 34

1.

Increasing the Clinical Potential and Applications of Anti-HIV Antibodies.

Hua CK, Ackerman ME.

Front Immunol. 2017 Nov 28;8:1655. doi: 10.3389/fimmu.2017.01655. eCollection 2017. Review.

2.

The HIV Genomic Incidence Assay Meets False Recency Rate and Mean Duration of Recency Infection Performance Standards.

Park SY, Love TMT, Reynell L, Yu C, Kang TM, Anastos K, DeHovitz J, Liu C, Kober KM, Cohen M, Mack WJ, Lee HY.

Sci Rep. 2017 Aug 7;7(1):7480. doi: 10.1038/s41598-017-07490-4.

3.

Neutralizing Antibodies Against a Specific Human Immunodeficiency Virus gp41 Epitope are Associated With Long-term Non-progressor Status.

Lucar O, Su B, Potard V, Samri A, Autran B, Moog C, Debré P, Vieillard V.

EBioMedicine. 2017 Aug;22:122-132. doi: 10.1016/j.ebiom.2017.07.007. Epub 2017 Jul 11.

4.

HIV-1 clade C escapes broadly neutralizing autologous antibodies with N332 glycan specificity by distinct mechanisms.

Deshpande S, Patil S, Kumar R, Hermanus T, Murugavel KG, Srikrishnan AK, Solomon S, Morris L, Bhattacharya J.

Retrovirology. 2016 Aug 30;13(1):60. doi: 10.1186/s12977-016-0297-2.

5.

Holes in the Glycan Shield of the Native HIV Envelope Are a Target of Trimer-Elicited Neutralizing Antibodies.

McCoy LE, van Gils MJ, Ozorowski G, Messmer T, Briney B, Voss JE, Kulp DW, Macauley MS, Sok D, Pauthner M, Menis S, Cottrell CA, Torres JL, Hsueh J, Schief WR, Wilson IA, Ward AB, Sanders RW, Burton DR.

Cell Rep. 2016 Aug 30;16(9):2327-38. doi: 10.1016/j.celrep.2016.07.074. Epub 2016 Aug 18.

6.

HIV-1 escapes from N332-directed antibody neutralization in an elite neutralizer by envelope glycoprotein elongation and introduction of unusual disulfide bonds.

van den Kerkhof TL, de Taeye SW, Boeser-Nunnink BD, Burton DR, Kootstra NA, Schuitemaker H, Sanders RW, van Gils MJ.

Retrovirology. 2016 Jul 7;13(1):48. doi: 10.1186/s12977-016-0279-4.

7.

Maintenance of HIV-Specific Memory B-Cell Responses in Elite Controllers Despite Low Viral Burdens.

Buckner CM, Kardava L, Zhang X, Gittens K, Justement JS, Kovacs C, McDermott AB, Li Y, Sajadi MM, Chun TW, Fauci AS, Moir S.

J Infect Dis. 2016 Aug 1;214(3):390-8. doi: 10.1093/infdis/jiw163. Epub 2016 Apr 27.

8.

Effects of neutralizing antibodies on escape from CD8+ T-cell responses in HIV-1 infection.

Wikramaratna PS, Lourenço J, Klenerman P, Pybus OG, Gupta S.

Philos Trans R Soc Lond B Biol Sci. 2015 Aug 19;370(1675). pii: 20140290. doi: 10.1098/rstb.2014.0290.

9.

Virological features associated with the development of broadly neutralizing antibodies to HIV-1.

Moore PL, Williamson C, Morris L.

Trends Microbiol. 2015 Apr;23(4):204-11. doi: 10.1016/j.tim.2014.12.007. Epub 2015 Jan 5. Review.

11.

An investigation of the breadth of neutralizing antibody response in cats naturally infected with feline immunodeficiency virus.

Bęczkowski PM, Logan N, McMonagle E, Litster A, Willett BJ, Hosie MJ.

J Gen Virol. 2015 Mar;96(Pt 3):671-80. doi: 10.1099/vir.0.071522-0. Epub 2014 Nov 13.

12.

Simulation of B cell affinity maturation explains enhanced antibody cross-reactivity induced by the polyvalent malaria vaccine AMA1.

Chaudhury S, Reifman J, Wallqvist A.

J Immunol. 2014 Sep 1;193(5):2073-86. doi: 10.4049/jimmunol.1401054. Epub 2014 Jul 30.

13.

Characterization of a monoclonal antibody to a novel glycan-dependent epitope in the V1/V2 domain of the HIV-1 envelope protein, gp120.

Doran RC, Morales JF, To B, Morin TJ, Theolis R Jr, O'Rourke SM, Yu B, Mesa KA, Berman PW.

Mol Immunol. 2014 Nov;62(1):219-226. doi: 10.1016/j.molimm.2014.06.025. Epub 2014 Jul 11.

14.

The genealogical population dynamics of HIV-1 in a large transmission chain: bridging within and among host evolutionary rates.

Vrancken B, Rambaut A, Suchard MA, Drummond A, Baele G, Derdelinckx I, Van Wijngaerden E, Vandamme AM, Van Laethem K, Lemey P.

PLoS Comput Biol. 2014 Apr 3;10(4):e1003505. doi: 10.1371/journal.pcbi.1003505. eCollection 2014 Apr.

15.

HIV-1 envelope glycoprotein signatures that correlate with the development of cross-reactive neutralizing activity.

van den Kerkhof TL, Feenstra KA, Euler Z, van Gils MJ, Rijsdijk LW, Boeser-Nunnink BD, Heringa J, Schuitemaker H, Sanders RW.

Retrovirology. 2013 Sep 23;10:102. doi: 10.1186/1742-4690-10-102.

16.

HIV-1 envelope glycoprotein resistance to monoclonal antibody 2G12 is subject-specific and context-dependent in macaques and humans.

Malherbe DC, Sanders RW, van Gils MJ, Park B, Gomes MM, Schuitemaker H, Barnett S, Haigwood NL.

PLoS One. 2013 Sep 9;8(9):e75277. doi: 10.1371/journal.pone.0075277. eCollection 2013.

17.

Selected HIV-1 Env trimeric formulations act as potent immunogens in a rabbit vaccination model.

Heyndrickx L, Stewart-Jones G, Jansson M, Schuitemaker H, Bowles E, Buonaguro L, Grevstad B, Vinner L, Vereecken K, Parker J, Ramaswamy M, Biswas P, Vanham G, Scarlatti G, Fomsgaard A; NGIN Consortium.

PLoS One. 2013 Sep 2;8(9):e74552. doi: 10.1371/journal.pone.0074552. eCollection 2013.

18.

Evidence for a continuous drift of the HIV-1 species towards higher resistance to neutralizing antibodies over the course of the epidemic.

Bouvin-Pley M, Morgand M, Moreau A, Jestin P, Simonnet C, Tran L, Goujard C, Meyer L, Barin F, Braibant M.

PLoS Pathog. 2013;9(7):e1003477. doi: 10.1371/journal.ppat.1003477. Epub 2013 Jul 4.

19.

HIV-1 Env C2-V4 diversification in a slow-progressor infant reveals a flat but rugged fitness landscape.

Smith SA, Wood C, West JT.

PLoS One. 2013 Apr 29;8(4):e63094. doi: 10.1371/journal.pone.0063094. Print 2013.

20.

Multiple pathways of escape from HIV broadly cross-neutralizing V2-dependent antibodies.

Moore PL, Sheward D, Nonyane M, Ranchobe N, Hermanus T, Gray ES, Abdool Karim SS, Williamson C, Morris L.

J Virol. 2013 May;87(9):4882-94. doi: 10.1128/JVI.03424-12. Epub 2013 Feb 13.

Supplemental Content

Support Center